AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== Expression == In humans, GHBP is formed by post-translational modification after the complete transcription and translation of the growth hormone receptor (GHR) gene into the cell-surface receptor protein. The gene that codes for GHR (and inherently GHBP) is on Chromosome 5. A precursor messenger RNA (mRNA) from the complete gene first is transcribed and then spliced to encode the full receptor protein. This mature mRNA is composed of exons. Exons are peptide encoding regions of DNA genes that remain in the transcript after splicing and during the maturation of mRNA. The mRNA transcript encodes for a receptor protein that is made up of three distinct parts: an intracellular domain, a transmembrane domain, and an extracellular domain. Specifically, part of exon 2 and exons 3-7 of the GHR gene will translate to amino acids that make up the extracellular domain of GHR. This extracellular domain physically binds GH in the receptor-ligand interaction.
== Clinical signs == Many signs are associated with PPID, but only a subset of these is displayed in any single horse. Some horses may present with chronic laminitis without other overt signs of the disease.
=== EC 1.17.99 With unknown physiological acceptors === EC 1.17.99.1: Now EC 1.17.9.1, 4-methylphenol dehydrogenase (hydroxylating) EC 1.17.99.2: ethylbenzene hydroxylase EC 1.17.99.3: 3α,7α,12α-trihydroxy-5β-cholestanoyl-CoA 24-hydroxylase EC 1.17.99.4: uracil/thymine dehydrogenase EC 1.17.99.5: Now classified as EC 1.17.98.1, bile-acid 7α-dehydroxylase EC 1.17.99.6: epoxyqueuosine reductase EC 1.17.99.7: Now classified as EC 1.17.98.4, formate dehydrogenase (hydrogenase) EC 1.17.99.8: limonene dehydrogenase EC 1.17.99.9: heme a synthase EC 1.17.99.10: steroid C-25 hydroxylase EC 1.17.99.11: 3-oxo-Δ1-steroid hydratase/dehydrogenase
A 2023 study by Singh et al using higher resolution markers than previous studies found that there was higher gene flow from South India to the Sinhalese than from North India, with the Sinhalese sharing the highest Identity by descent with Tamils, especially the Piramalai Kallars, compared to the other Indian populations studied. The study also found heightened sharing with the Maratha of India, consistent with a West Eurasian contribution .This excess sharing of segments suggests common roots of Sinhala with the Marāṭhā corroborating the linguistic hypothesis of Lazarus Geiger, Ralph Lilley Turner, and George van Driem. The total Sinhalese sample size used was 9 individuals. A 2025 study by Aragon et al again found that the Sinhalese were genetically closer to populations from South India than to populations from North India. The study also failed to find high genetic affinities and allele sharing with North Indian populations. The study collected 35 Sinhalese samples from multiple cities (Galle, Anuradhapura, Kandy, Matale, Ratnapura, Kurunegala, Colombo, Kalutara, and Gampaha) in order to build a more representative picture.
Sources: en.wikipedia.org
In this instance reversal of paralysis will not occur until the damaged terminal axons at the neuromuscular junction have recovered, this may take days or weeks. The drug may also be used for reversal of neuromuscular blockade at the end of a surgical procedure.
=== The Final Hours of Portal 2 === The Final Hours of Portal 2 is a digital book written and created by Geoff Keighley released on May 17, 2011. This digital book gives insight on the creation of Portal 2. Keighley had previously worked as an editor at GameSpot, writing several 10,000-word "Final Hours" pieces on various games where he visited the studios during the late development phases to document the creation of the game. One piece, "The Final Hours of Half-Life 2", allowed Keighley to interact with Valve during 2003 and 2004 and talk with the staff as they completed work on Half-Life 2. Keighley wanted to recreate a similar work for Portal 2, with focus on making it an interactive work for the iPad. Keighley was granted "fly on the wall" access to Valve when Portal 2 was being produced. The initial iPad release was written by Keighley with work by Joe Zeff Design, a studio that had also produced digital applications for Time magazine. The interactive work provides movie clips and short applications to demonstrate the various mechanics of the game and stages of the game's development. The work was later ported into a non-interactive eBook, and into an application with the same iPad interactivity on the Steam platform. With the iPad and Steam version, Keighley is able to offer live updates to the work; upon release of the "Peer Review" downloadable content pack, the work was updated with an additional chapter discussing the creation of the new content and what new features players could expect in the future from Portal 2.
== Pharmacokinetics == Trelagliptin's uniquely designed structure enhances its chemical stability and resistance to metabolic degradation. It binds strongly to the DPP-4 enzyme, with a slow dissociation rate (~30 minutes), compared to sitagliptin (3.5 min) and vildagliptin (<2 min). This prolonged binding contributes to its sustained DPP-4 inhibition. Trelagliptin has a long elimination half-life of approximately 54.3 hours. A 100 mg once-weekly dose maintained 77.4% DPP-4 inhibition 7 days post-dose. The drug reaches steady-state plasma levels (20.00–21.60 ng/mL) by week 4. These properties support its effective once-weekly dosing regimen.
=== Inorganic === Hemolymph is composed of water, inorganic salts (mostly sodium, chlorine, potassium, magnesium, and calcium), and organic compounds (mostly carbohydrates, proteins, and lipids). The primary oxygen transporter molecule is hemocyanin.
The 8th Air Force started operations from Britain in August 1942. At first, because of the limited scale of operations, no conclusive evidence showed American doctrine was failing. In the 26 operations flown to the end of 1942, the loss rate had been under 2%. In January 1943, at the Casablanca Conference, the Allies formulated the Combined Bomber Offensive (CBO) plan for "round-the-clock" bombing – USAAF daytime operations complementing the RAF nighttime raids on industrial centers. In June 1943, the Combined Chiefs of Staff issued the Pointblank Directive to destroy the Luftwaffe's capacity before the planned invasion of Europe, putting the CBO into full implementation. German daytime fighter efforts were, at that time, focused on the Eastern Front and several other distant locations. Initial efforts by the 8th met limited and unorganized resistance, but with every mission, the Luftwaffe moved more aircraft to the west and quickly improved their battle direction. In late 1943, the 8th Air Force's heavy bombers conducted a series of deep penetration raids into Germany, beyond the range of escort fighters. The Schweinfurt–Regensburg mission in August lost 60 B-17s of a force of 376, the 14 October attack lost 77 of a force of 291—26% of the attacking force.
Sources: en.wikipedia.org
==== MeSH D12.125.119 – amino acids, dicarboxylic ==== MeSH D12.125.119.075 – 2-aminoadipic acid MeSH D12.125.119.170 – aspartic acid MeSH D12.125.119.170.150 – d-aspartic acid MeSH D12.125.119.170.275 – isoaspartic acid MeSH D12.125.119.170.400 – n-methylaspartate MeSH D12.125.119.170.700 – potassium magnesium aspartate MeSH D12.125.119.270 – carbocysteine MeSH D12.125.119.307 – cystathionine MeSH D12.125.119.369 – cystine MeSH D12.125.119.450 – glutamic acid MeSH D12.125.119.450.150 – 1-carboxyglutamic acid MeSH D12.125.119.450.400 – glutamates MeSH D12.125.119.450.400.700 – polyglutamic acid MeSH D12.125.119.450.400.800 – sodium glutamate MeSH D12.125.119.658 – homocystine
Anise tea, made from either the seeds or the leaves Asiatic penny-wort leaf, in South Asia and Southeast Asia Artichoke tea Commiphora gileadensis tea, in the Hijaz region of western Arabia. Bael fruit tea Barley tea, East Asian drink with roasted barley Bee balm Boldo, used in South America Burdock; the seeds, leaves, and roots have been used Butterfly pea flower tea (from Clitoria ternatea), also called "Blue tea" since it produces a blue infusion Caraway, tea made from the seeds Catnip, tea used as a relaxant, sedative, and to calm Chamomile, both Matricaria chamomilla and Chamaemelum nobile can be used Che dang, bitter tea made from Ilex causue leaves Chinese knotweed tea Chrysanthemum tea, made from dried flowers Cinnamon tea Clover tea, made from the blossoms Cerasse, bitter Jamaican herb Citrus peel, including bergamot, lemon and orange peel Dandelion coffee, which does not contain caffeine despite the name Dill tea Dried lime tea, made from dried limes common in western Asia Echinacea tea Elderberry European mistletoe (Viscum album), (steep in cold water for 2–6 hours) Essiac tea, blended herbal tea Fennel Gentian Ginger tea, made from the ginger root, can be made into herbal tea, known in the Philippines as salabat Ginkgo biloba Ginseng tea, a common tea in China and Korea, commonly used as a stimulant and as a caffeine substitute Goji berry tea Hawthorn Hibiscus tea (often blended with rose hip), a common tea in the Middle East or Asia Honeybush, similar to rooibos and grows in a nearby area of South Africa, but tastes slightly sweeter.
=== Regulation of cholesterol synthesis === Biosynthesis of cholesterol is directly regulated by the cholesterol levels present, though the homeostatic mechanisms involved are only partly understood. A higher intake of food leads to a net decrease in endogenous production, whereas a lower intake of food has the opposite effect. The main regulatory mechanism is the sensing of intracellular cholesterol in the endoplasmic reticulum by the protein SREBP (sterol regulatory element-binding protein 1 and 2). In the presence of cholesterol, SREBP is bound to two other proteins: SCAP (SREBP cleavage-activating protein) and INSIG-1. When cholesterol levels fall, INSIG-1 dissociates from the SREBP-SCAP complex, which allows the complex to migrate to the Golgi apparatus. Here SREBP is cleaved by S1P and S2P (site-1 protease and site-2 protease), two enzymes that are activated by SCAP when cholesterol levels are low. The cleaved SREBP then migrates to the nucleus and acts as a transcription factor to bind to the sterol regulatory element (SRE), which stimulates the transcription of many genes. Among these are the low-density lipoprotein (LDL) receptor and HMG-CoA reductase. The LDL receptor scavenges circulating LDL from the bloodstream, whereas HMG-CoA reductase leads to an increase in endogenous production of cholesterol. A large part of this signaling pathway was clarified by Dr. Michael S. Brown and Dr. Joseph L. Goldstein in the 1970s. In 1985, they received the Nobel Prize in Physiology or Medicine for their work.
Trinity admonishes Neo to run, but he stands his ground, having begun to believe that he may be the One. Neo and Smith draw guns and fire them empty, but are able to effortlessly dodge each other's fire. Neo skillfully engages Smith in hand-to-hand combat, almost seeming to be Smith's equal. In the end, Neo is briefly incapacitated and held by Smith as a subway train approaches, but at the last minute, he is able to get free and backflip up onto the platform, leaving Smith to be run over. However, the agent possesses the body of the conductor and emerges from the train. Neo, realizing that the agents' ability to possess other bodies makes this a fight he cannot win, flees the subway station. Pursued by Smith and his fellow agents, Neo is able to evade them and reach the location of the landline phone, just to be ambushed and fatally shot in the chest by Smith. Trinity, seeing Neo die in the real world while his mind is still in the Matrix, tells his evidently lifeless body that the Oracle had foretold that she would fall in love with the One. When kissed by Trinity, Neo is revived, finally fully emerging as the One. When the agents try to kill him again, Neo simply raises his hand, and the bullets freeze in mid-air, then drop harmlessly to the ground. It is then shown that he is able to perceive, interpret, and alter the computer code of the Matrix. Completely believing in his new-found powers, he effortlessly fends off agent Smith before forcing himself into the agent's body and destroying it from within. The other two agents quickly flee.
Dermatitis is a term used for different types of skin inflammation, typically characterized by itchiness, redness and a rash. Dermatitis may also be called eczema, but the same term is often used for the most common type of skin inflammation, atopic dermatitis. Dermatitis can be managed with moisturizers and prescription anti-inflammatory treatments, whereas topical antimicrobials, antiseptics, and antihistamines are not recommended by dermatologists.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.